Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020
Hospital-acquired pneumonia also called as healthcare associated pneumonia or nosocomial pneumonia is acquired in hospital premises. Unlike community acquired pneumonia hospital acquired pneumonia is mainly caused due to multidrug resistant microorganisms. The report analyzes the market for late stage candidates for treatment of nosocomial pneumonia, and also provides a detailed review of drugs in early stages of clinical trials. The report studies and estimates market for six late stage along with an elucidation of ten early stage candidates for nosocomial pneumonia treatment.
Hospital-acquired pneumonia also called as healthcare associated pneumonia or nosocomial pneumonia is acquired in hospital premises. Unlike community acquired pneumonia hospital acquired pneumonia is mainly caused due to multidrug resistant microorganisms. The report analyzes the market for late stage candidates for treatment of nosocomial pneumonia, and also provides a detailed review of drugs in early stages of clinical trials. The report studies and estimates market for six late stage along with an elucidation of ten early stage candidates for nosocomial pneumonia treatment.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Pipeline</strong> <strong>Analysis</strong> <strong>of</strong> <strong>Hospital</strong><br />
<strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Drugs</strong> <strong>Market</strong><br />
7.8.5 Recent Developments<br />
7.9 Valneva SE<br />
7.9.1 Company Overview<br />
7.9.2 Financial Overview<br />
7.9.3 Product Portfolio<br />
7.9.4 Business Strategies<br />
7.9.5 Recent Developments<br />
List <strong>of</strong> Figures<br />
FIG. 1 <strong>Hospital</strong> <strong>Acquired</strong> <strong>Pneumonia</strong>: Drug <strong>Pipeline</strong><br />
FIG. 2 <strong>Hospital</strong> <strong>Acquired</strong> <strong>Pneumonia</strong> Phase III C<strong>and</strong>idates, <strong>Market</strong> <strong>Share</strong>, <strong>2020</strong> (Value %)<br />
FIG. 3 Value Chain <strong>Analysis</strong><br />
FIG. 4 Porter’s Five Forces <strong>Analysis</strong>: <strong>Global</strong> <strong>Hospital</strong> <strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Market</strong><br />
FIG. 5 Revenue trend <strong>of</strong> major br<strong>and</strong>ed drugs <strong>and</strong> vaccines in nosocomial pneumonia market (USD Million)<br />
FIG. 6 <strong>Global</strong> Tedizolid Phosphate <strong>Market</strong> Revenue, 2017 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
FIG. 7 <strong>Global</strong> Ceftolozane/Tazobactam <strong>Market</strong> Revenue, 2017 <strong>–</strong> <strong>2020</strong> (USD million)<br />
FIG. 8 <strong>Global</strong> Ceftazidime/Avibactam <strong>Market</strong> Revenue, 2017 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
FIG. 9 <strong>Global</strong> Amikacin Inhale <strong>Market</strong> Revenue, 2016 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
FIG. 10 <strong>Global</strong> Plazomicin <strong>Market</strong> Revenue, 2017 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
FIG. 11 <strong>Global</strong> Synflorix <strong>Market</strong> Revenue, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
Transparency <strong>Market</strong> Research<br />
11
Change language